Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2006

View Archived Issues

DTA-H19: a new DNA-based cancer therapy

7TM Pharma receives milestone payment from research collaboration with P&G

BGC-20-761 improves in vivo cognitive benefits mediated via 5-HT6 antagonism

Spine Wave cleared to begin pilot trial of NuCore Injectable Nucleus

Rexahn partners with University of Maryland in nanomedicine

Nastech Pharmaceutical acquires RNAi program targeting influenza from Galenea

Targeting of IGF-IR and Bcl-2 eradicates androgen-independent prostate cells in vitro

mGluR III agonists: New restorers of neural circuits in Parkinson's disease?

Xanthus Life Sciences changes name to Xanthus Pharmaceuticals

Celtic Pharma licenses IDEA's Transfersome technology and derma pipeline

AP-5346 studied in head and neck cancer

Phase I study assesses safety of gene therapy product AGTC-0106

ZIO-201 begins phase I/II study in sarcoma

Alcon withdraws application to extend European approval of Opatanol

OrthoLogic to acquire certain assets of AzERx

Cyproxan receives Japanese approval for new indication

PEP-005 Topical gel well tolerated in dose-escalation study

In vivo metabolism of new combi-molecule facilitates potent multiple tumor targeting

Indole-3-carbinol and genistein target BRCA1 and BRCA2 genes

LA-12 overcomes cisplatin resistance in ovarian tumors in mice

Novel antiinfective agents disclosed in recent patent literature

Recent patents disclose novel ophthalmic drugs

New melanocortin MC4 receptor ligands prepared and tested by SCRAS

Phase II trial assesses cortisol synthesis inhibitor DIO-902 for type 2 diabetes

European approval for Rotarix

Oracea filed for approval in U.K.

EluSys presents new efficacy data for Anthim anthrax therapeutic

Ampligen plus oseltamivir or zanamivir synergistically inhibits avian influenza

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...